Incyte Corporation
INCY Healthcare Biotechnology
Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024. In the quarter to June 2026, revenue grew 37.7%, EPS grew 39.7%, free cash flow grew 1,829.5% and total debt fell 10.5%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years.
Follow INCY
Incyte Corporation (INCY) Revenue
Incyte Corporation's revenue for fiscal 2025 was $5.1B, up 21.2% from $4.2B in fiscal 2024. Over the twelve months to 30 June 2026 it was $5.8B. Over the past ten years it has ranged from $753.8M (fiscal 2015) to $5.1B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 10 consecutive fiscal years. Incyte Corporation ranks 4th of 402 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $5.1B | 21.22% |
| FY2024 | $4.2B | 14.76% |
| FY2023 | $3.7B | 8.87% |
| FY2022 | $3.4B | 13.67% |
| FY2021 | $3.0B | 11.98% |
| FY2020 | $2.7B | 23.53% |
| FY2019 | $2.2B | 14.71% |
| FY2018 | $1.9B | 22.50% |
| FY2017 | $1.5B | 38.93% |
| FY2016 | $1.1B | 46.70% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $1.7B | 31.54% |
| Mar 2026 | $1.3B | (15.54%) |
| Dec 2025 | $1.5B | 10.31% |
| Sep 2025 | $1.4B | 12.38% |
| 42 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| INCY Incyte Corporation | $5.8B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $4.8B |
| GMAB Genmab A/S Sponsored ADR compare | $4.1B |
| BNTX BioNTech SE Sponsored ADR compare | $3.0B |
| RPRX Royalty Pharma PLC compare | $2.5B |
| EXEL Exelixis, Inc. compare | $2.4B |
| ASND Ascendis Pharma A/S compare | $1.2B |
| INSM Insmed, Inc. compare | $1.1B |
| ROIV Roivant Sciences Ltd. compare | $7.5M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on INCY
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement